

## Special Issue

# Research, Advances, Challenges and Perspectives in the Development of Vaccines against Dengue, Zika and Chikungunya Viruses

### Message from the Guest Editors

To establish vaccines, it is necessary to define the host-pathogen interaction mechanisms and especially the molecular determinants of virulence. Among the challenges, it is necessary to consider the existence of the ADE phenomenon, a possible co-circulation of two or more of these viruses in endemic areas and the high prevalence of Guillain-Barré syndromes during some of these viral infections. A candidate vaccine must therefore be able to avoid inducing this type of response in humans and must be able to be used by the most vulnerable populations in endemic areas such as newborns or pregnant women. The purpose of this Special Issue “Research, advances, challenges and perspectives in the development of vaccines against Dengue, Zika and Chikungunya viruses” is to present the latest research results that advance our knowledge on the progress conception of vaccine strategies against these arboviruses. It is open to the submission of manuscripts, reviews, research, short communications, hypothesis, perspectives and point of view, that describe research or idea that can improve our knowledge on this issue for vaccines.

### Guest Editors

Dr. Wildriss Viranaicken

PIMIT, Processus Infectieux en Milieu Insulaire Tropical, Université de La Réunion, INSERM UMR 1187, CNRS 9192, IRD 249, Plateforme CYROI, 97490 Sainte-Clotilde, Ile de La Réunion, France

Dr. Pascale Krejbich-Trotot

CYROI Technological Platform, Mixed Unit for Infectious Processes in Tropical Island Environments, University of Réunion, Réunion, France

### Deadline for manuscript submissions

closed (31 August 2021)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/37673](https://mdpi.com/si/37673)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).